An immunosurveillance system for tumor-associated antigens (TAAs) plays an important role in the elimination of cancer cells during the initial stage. Although cancer immunotherapy targeting TAAs has progressed steadily with the development of various vaccine strategies, excellent therapeutic e‹cacy, as evidenced by marked tumor regression and complete response, has not been reported in a clinical setting to date. To improve the therapeutic eŠects of cancer immunotherapy, we are attempting to establish an innovative concept, the``cell delivery system,'' capable of better controlling the tra‹cking and biodistribution of immune cells by applying chemokine-chemokine receptor coupling, which regulates leukocytic migration and inˆltration of local sites in the living body. This review introduces our approaches that employ an Arg-Gly-Asp (RGD)ˆber-mutant adenovirus vector encoding the chemokine or chemokine receptor gene in cancer immunotherapy.
The migration of DCs from administration site to regional lymph nodes is critical for the priming of T cells in DC-based immunotherapy. However, the poor migratory ability of antigen-delivered DCs limits the induction of a potent immune response. On the other hand, DCs transduced e‹ciently with the CCR7 gene may adequately respond to CCL21, which is constitutively released from lymphoid tissue, and acquire migratory ability to lymph nodes. Consequently, antigen-delivered DCs with CCR7 transduction can enhance the initiation and ampliˆcation of the T cell-dependent immune response. DCs derived from EGFP-transgenic mice were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI, and then were intradermally injected into the left ‰ank of C57BL/6 mice at 2×10 6 cells/50 ml. Two days later, the draining inguinal lymph nodes were collected from these mice, and a single cell suspension was prepared. The abundance of EGFP-positive DCs was assessed by ‰ow cytometric analysis acquiring 500000 events. The number of DCs that had migrated into draining lymph nodes was calculated by multiplying the EGFP-positive DC-frequency by the total number of isolated lymph node cells. 
